Zuberitamab

DRUG5 trials

Sponsors

Sun Yat-sen University, Peking University Third Hospital, Institute of Hematology & Blood Diseases Hospital, China, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Children's Hospital of Fudan University

Conditions

EBV InfectionFollicular Lymphoma (FL)HSCTMantle Cell Lymphoma (MCL)Marginal Zone Lymphoma(MZL)Nephrotic SyndromePOZ

Phase 2

Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma

Not yet recruitingNCT06757894

Sun Yat-sen UniversityFollicular Lymphoma (FL)

Start: 2025-02-01End: 2034-02-01Target: 50Updated: 2025-01-03

Zuberitamab for EBV Infection Post-Allo-HSCT

Not yet recruitingNCT07261215

Institute of Hematology & Blood Diseases Hospital, ChinaEBV Infection, HSCT

Start: 2026-01-14End: 2026-10-31Target: 20Updated: 2025-12-03

Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL

Active, not recruitingNCT07480863

Cancer Institute and Hospital, Chinese Academy of Medical SciencesMarginal Zone Lymphoma(MZL)

Start: 2025-10-01End: 2029-10-02Target: 65Updated: 2026-04-02

Phase 3

Zuberitamab in the First Episode of Paediatric Nephrotic Syndrome

Not yet recruitingNCT07765914

Children's Hospital of Fudan UniversityNephrotic Syndrome

Start: 2026-08-20End: 2028-12-31Target: 120Updated: 2026-08-14

Unknown Phase

Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma

RecruitingNCT07257510

Peking University Third HospitalMantle Cell Lymphoma (MCL), POZ

Start: 2025-08-01End: 2028-08-01Target: 34Updated: 2025-12-02